Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085593 | 0.98 | SLC6A4 (0.72) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL9027256 | 0.87 | SLC6A4 (0.80) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL15862815 | 0.86 | SLC6A4 (0.74) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL8458076 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3466313 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL1981732 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL1981733 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL27997201 | 0.82 | SLC6A4 (0.74) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL15043689 | 0.81 | SLC6A4 (0.66) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5085612 | 0.81 | SLC6A3 (0.76) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | SLC6A4 4300/4885SLC6A3 4353/4885SLC6A2 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.